PhysOrg.com notes continuing improvement in prospective cancer therapies based on dendrimers: "After a single intravenous injection, every mouse treated with the dendrimer-drug construct survived until the end of the 60-day experiment and every mouse showed complete tumor regression. In contrast, none of the mice treated with only doxorubicin survived, which an average survival time of only 24 days." A single shot cure for cancer, in other words - nice work. Enthusiasm is in view out there in the nanotechnology community: "There's that word: cures! If nanotechnology, at this early stage, can make a difference for cancer, this should greatly increase public support for nanotech R&D, especially nanomedicine. Then we can go after heart disease, Alzheimer's, AIDS, and ... aging itself. It's all about how the molecules are arranged."

Link: http://www.physorg.com/news82653370.html